Bionano Genomics (BNGO)
NASDAQ:BNGO
Want to see BNGO full AI Analyst Report?
BNGO Stock Chart & Stats
$1.62
-$0.04(-14.25%)
At close: 4:00 PM EST
$1.62
-$0.04(-14.25%)
Day’s Range― - ―
52-Week Range$1.06 - $5.50
Previous CloseN/A
Volume11.48M
Average Volume (3M)170.51K
Market Cap
$13.08M
Enterprise Value$7.13M
Total Cash (Recent Filing)$24.67M
Total Debt (Recent Filing)$17.01M
Price to Earnings (P/E)―
Beta1.54
Next Earnings
Jul 30, 2026EPS Estimate
-0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.80
Shares Outstanding11,475,000
10 Day Avg. Volume142,259
30 Day Avg. Volume170,511
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.19
Price to Sales (P/S)0.29
P/FCF Ratio-0.51
Enterprise Value/Market Cap0.55
Enterprise Value/Revenue0.25
Enterprise Value/Gross Profit0.53
Enterprise Value/Ebitda-0.33
Forecast
1Y Price Target
$5.00Price Target Upside208.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.6
Revenue Forecast (FY)$32.14M
Bulls Say, Bears Say
Bulls Say
Consumables Recurring RevenueIncreasing consumables sales indicate progressing conversion from instrument placements to recurring usage. A higher share of consumables stabilizes revenues, improves predictability and margins over time, and leverages installed instruments to create durable pull-through economics as labs scale OGM workflows.
Growing Instrument UtilizationRising flow-cell volumes, especially repeat sales to existing customers, signal deeper lab adoption and higher sample throughput. Sustained utilization drives recurring revenue, supports consumables margin expansion, and reduces reliance on new system sales for growth—strengthening the underlying business model over months.
Improved Reimbursement EconomicsMaterial reimbursement increases raise per-test economics and lower adoption barriers for clinical labs and payers. Higher, stable CPT payments make OGM more commercially viable, encouraging routine use in diagnostics and creating a structural tailwind for durable clinical revenue adoption and recurring test volumes.
Bears Say
Persistent Cash BurnSustained negative free cash flow means the company will likely rely on external financing absent material margin or revenue scale improvements. This creates dilution and execution risk, constrains investment in commercialization, and poses a multi‑quarter threat to strategic initiatives if cash runway shortens.
Revenue And Margin FragilityA multi‑period revenue decline and low gross margins indicate the business has yet to reach scale economics. Low margin structure and revenue variability make profitability sensitive to mix shifts and single large deals, complicating forecasts and requiring sustained growth and cost control to achieve durable profitability.
Leadership & Execution RiskSenior leadership turnover and interim responsibilities concentrate decision‑making in a board member, risking strategic continuity during a critical commercialization phase. Such transitions can slow hiring, partnerships, and clinical initiatives, elevating execution risk over several quarters as a permanent leadership team is sourced and onboarded.
BioNano Genomics News
BNGO FAQ
What was Bionano Genomics’s price range in the past 12 months?
Bionano Genomics lowest stock price was $1.06 and its highest was $5.50 in the past 12 months.
What is Bionano Genomics’s market cap?
Bionano Genomics’s market cap is $13.08M.
When is Bionano Genomics’s upcoming earnings report date?
Bionano Genomics’s upcoming earnings report date is Jul 30, 2026 which is in 39 days.
How were Bionano Genomics’s earnings last quarter?
Bionano Genomics released its earnings results on May 13, 2026. The company reported -$0.76 earnings per share for the quarter, beating the consensus estimate of -$0.88 by $0.12.
Is Bionano Genomics overvalued?
According to Wall Street analysts Bionano Genomics’s price is currently Undervalued.
Does Bionano Genomics pay dividends?
Bionano Genomics does not currently pay dividends.
What is Bionano Genomics’s EPS estimate?
Bionano Genomics’s EPS estimate is -0.69.
How many shares outstanding does Bionano Genomics have?
Bionano Genomics has 11,475,000 shares outstanding.
What happened to Bionano Genomics’s price movement after its last earnings report?
Bionano Genomics reported an EPS of -$0.76 in its last earnings report, beating expectations of -$0.88. Following the earnings report the stock price went down -4.8%.
Which hedge fund is a major shareholder of Bionano Genomics?
Currently, no hedge funds are holding shares in BNGO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bionano Genomics
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.
BNGO Company Deck
BNGO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized multiple positive operational and commercial developments: record Q1 flow cell unit sales, strong consumables growth, improved adjusted gross margin (49% vs 46% YoY), meaningful reimbursement wins that materially improve test economics, growing publication and clinical validation momentum, and balance sheet simplification through planned debt retirement. Offsetting these positives are continued revenue lumpiness (notably a 40% decline in software revenue due to a prior large sale), ongoing supply constraints that are improving, increased operating expenses ($9.1M vs $8.5M YoY) and a cash runway into 2027 with management not expecting cash flow breakeven in 2026. Overall, the call portrays improving commercialization traction and margin progress with material near-term financial and execution risks that management is addressing.View all BNGO earnings summariesBNGO Stock 12 Month Forecast
Average Price Target
$5.00
▲(208.64% Upside)
Technical Analysis
Ownership Overview
1.10% Insiders
1.17% Mutual Funds
0.61% Other Institutional Investors
96.40% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---